LYMPHIR™ (E7777)
Cutaneous T-cell lymphoma (CTCL)
ApprovedFDA Approved
Key Facts
Indication
Cutaneous T-cell lymphoma (CTCL)
Phase
Approved
Status
FDA Approved
Company
About Citius Pharmaceuticals
Citius Pharmaceuticals is a publicly traded, late-stage biopharma company focused on addressing unmet needs in critical care and oncology. The company has built a diversified pipeline with three main candidates, including the recently FDA-approved LYMPHIR™. With significant founder investment and a focus on products with large market potential, Citius aims to bring novel therapies to market faster.
View full company profileTherapeutic Areas
Other Cutaneous T-cell lymphoma (CTCL) Drugs
| Drug | Company | Phase |
|---|---|---|
| HyBryte™ (SGX301) | Soligenix | Phase 3 |